Biotek-snakken — Januar 2022
-
Data med tislelizumab blev udskudt et halvt år, hvilket fik en til at frygte, at kombineret ikke gjorde alverden ved ORR - og man derfor afventer at se en afsmitning på duration. Omvendt har både Neil og Ali nævnt, at både forbedring af ORR og duration er vigtig ved tislelizumab kombinationen, så det siger de vel ikke hvis de kan se at ORR ikke forbedres ret meget
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind